Cost, N., Renfro, L. A., Zibelman, M. R., Molina, A. M., Parikh, M., Pater, L. E., Tfirn, I., Mullen, E. A., Ehrlich, P. F., Tracy, E. T., Kalapurakal, J. A., Dome, J., Geller, J. I. (2025). AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4521